SCHEMBL1339409

SCHEMBL1339409

CCn1ccc(-c2ccc3c(c2)c2cc(-c4ccc(Cl)cc4Cl)c(=O)n(C)c2n3C)n1

nearest known ligand 0.36

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ HSD11B1 P28845 2/20 0.36
▸ GABRA1 P14867 5/20 0.35
▸ GABRG2 P18507 4/20 0.35
▸ GABRB3 P28472 4/20 0.35
▸ GABRA5 P31644 4/20 0.35
▸ F2RL3 Q96RI0 1/20 0.35
▸ CNR1 P21554 7/20 0.35
▸ CNR2 P34972 7/20 0.35
▸ KDM4E B2RXH2 1/20 0.35
▸ ALDH1A1 P00352 1/20 0.35
▸ GAA P10253 1/20 0.35
▸ HPGD P15428 1/20 0.35
▸ HSD17B10 Q99714 1/20 0.35
▸ MARS1 P56192 1/20 0.34
▸ MAPK8 P45983 1/20 0.33
▸ MAPK9 P45984 1/20 0.33
▸ MAPK10 P53779 1/20 0.33
▸ EGFR P00533 1/20 0.33
▸ ALOX5 P09917 1/20 0.33
▸ ADORA3 P0DMS8 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1337038 0.91 MARS1 (0.39) GABRA1CNR1CNR2KDM4EALDH1A1
SCHEMBL1338638 0.91 GABRA1 (0.34) GABRA1GABRG2GABRB3GABRA5MAPK8
SCHEMBL1338637 0.90 GABRA1 (0.38) HSD11B1GABRA1GABRG2GABRB3GABRA5
SCHEMBL1336826 0.90 CNR1 (0.35) HSD11B1GABRA1GABRG2GABRB3GABRA5
SCHEMBL1336965 0.89 HSD11B1 (0.33) HSD11B1GABRA1GABRG2GABRB3GABRA5
SCHEMBL1337210 0.89 KDM4E (0.37) HSD11B1GABRA1GABRG2GABRB3GABRA5
SCHEMBL1336885 0.89 CNR1 (0.37) CNR1CNR2KDM4EALDH1A1GAA
SCHEMBL1338200 0.88 GABRA1 (0.36) HSD11B1GABRA1GABRG2GABRB3GABRA5
SCHEMBL1339487 0.88 MCHR1 (0.41) KDM4EALDH1A1GAAHPGDHSD17B10
SCHEMBL1339250 0.87 CNR1 (0.34) GABRA1GABRG2GABRB3GABRA5CNR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8063061-B2 6-(2-amino-1,3-thiazol-4-yl)-3-(2,4-dichlorophenyl)-1-methyl-1,9-dihydro-2H-pyrido[2,3-b]indol-2-one; affinity for GABAA-receptor-associated omega modulatory sites SANOFI-AVENTIS (FR) 2011-11-22 — — US disclosed
EP-1940840-B1 6-HETEROARYLPYRIDOINDOLONE DERIVATIVES, THEIR PREPARATION AND THERAPEUTIC USE THEREOF SANOFI AVENTIS (FR) 2010-07-21 — — EP disclosed
US-20080262020-A1 6-Heteroarylpyridoindolone Derivatives, Their Preparation and Therapeutic Use Thereof SANOFI-AVENTIS (FR) 2008-10-23 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080262020-A1 6-Heteroarylpyridoindolone Derivatives, Their Preparation and Therapeutic Use Thereof CYP11B2, CYP11B1, CYP2D6 HSD11B1 107/4885GABRA1 1457/4885GABRG2 1617/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback